Factors associated with complicated erosive esophagitis: A Japanese multicenter, prospective, cross-sectional study

Table 1 Demographic and clinical characteristics of erosive esophagitis patients with and without complications n (%)

	With complications (n = 143)	Without complications (n = 1606)	P value
Sex (M/F)	74/69	970/636	0.043
Age (years old)	74.4 ± 11.0	67.4 ± 9.2	< 0.001
BMI (kg/m2)	23.2 ± 3.8	23.8 ± 3.5	0.074
General condition (tube-fed/bedridden/tube-fed + bedridden)	0/8/0	1/5/1	< 0.001
Consultation behavior (outpatient/inpatient/emergency patient)	90/26/27	1511/83/12	< 0.001
Smoking (never/current smoker/ex-smoker)	94/16/33	955/234/417	0.311
Duration of smoking cessation (yr)	16.8 ± 13.7	14.5 ± 13.3	0.359
Alcohol drinking			< 0.001
Never	76 (53.1)	711 (44.3)
Current
< 1 d per week	10 (7.0)	199 (12.4)
2-4 d per week	4 (2.8)	192 (12.0)
> 5 d per week	38 (26.6)	432 (26.9)
Ex-drinker	15 (10.5)	72 (4.5)
Duration of drinking cessation (yr)	8.8 ± 9.7	9.0 ± 10.8	0.957
Comorbidities
Hypertension	71 (49.7)	724 (45.1)	0.293
Diabetes mellitus	26 (18.2)	282 (17.6)	0.851
Hyperlipidemia	33 (23.1)	391 (24.3)	0.734
Cerebrovascular disease	22 (15.4)	83 (5.2)	< 0.001
Liver cirrhosis	4 (2.8)	30 (1.9)	0.441
Ischemic cardiac disease	13 (9.1)	85 (5.3)	0.058
Collagen disease	6 (4.2)	34 (2.1)	0.111
Dementia	13 (9.1)	11 (0.7)	< 0.001
Kyphosis	11 (7.7)	36 (2.2)	< 0.001
PPI treatment status			0.001
Never	20 (27.4)	395 (50.4)
Continuation therapy	40 (54.8)	251 (32.1)
On-demand therapy	2 (2.7)	35 (4.5)
Cessation	11(15.1)	102 (13.0)
Concomitant medication
Antithrombogenic	31 (21.7)	216 (13.5)	0.007
Aspirin	12 (8.4)	97 (6.0)	0.265
Antiplatelet agent	15 (10.5)	89 (5.5)	0.017
Anticoagulant agent	8 (5.6)	60 (3.7)	0.271
Antihypertensive drug	58 (40.6)	615 (38.3)	0.594
NSAID	17 (11.9)	91 (5.7)	0.003
Psychotropic	16 (11.2)	40 (2.5)	< 0.001

BMI: Body mass index; PPI: Proton pump inhibitor; NSAID: Nonsteroidal antiinflammatory drug.